Triglyceride-mediated pathways and coronary heart disease

The Lancet

Volumn 376, Issue 9745, 2010, Pages 956-

  Banerjee, Yajnavalka ^a   Taranikanti, Varna ^a,b   Bayoumi, Riad ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A; DRUG DERIVATIVE; HIGH DENSITY LIPOPROTEIN; PSYCHOSINE; PSYCHOSINE 3' SULFATE ESTER; PSYCHOSINE-3'-SULFATE ESTER; TRIACYLGLYCEROL;

BLOOD; CORONARY ARTERY DISEASE; GENETICS; HUMAN; METABOLISM; NOTE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

APOLIPOPROTEINS A; CORONARY DISEASE; HUMANS; LIPOPROTEINS, HDL; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOSINE; RISK FACTORS; TRIGLYCERIDES;

EID: 77956943443     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61447-X     Document Type: Letter

References (4)

1. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies Lancet 375 2010 1634 1639
2. J Schiller, O Zschornig, M Petkovic, M Muller, J Arnhold, K Arnold Lipid analysis of human HDL and LDL by MALDI-TOF mass spectrometry and (31)P-NMR J Lipid Res 42 2001 1501 1508
3. JR Nofer, M van der Giet, M Tolle HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J Clin Invest 113 2004 569 581
4. PW Shaul, C Mineo HDL action on the vascular wall: is the answer NO? J Clin Invest 113 2004 509 513